

Ren-Olivier Casasnovas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2948797/rene-olivier-casasnovas-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82
papers

4,341
citations

27
h-index

65
g-index

89
ext. papers

5,593
ext. citations

7.3
avg, IF

4.66
L-index

#	Paper	IF	Citations
82	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101777	2.2	1
81	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.. <i>Cancers</i> , 2022 , 14,	6.6	1
80	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. <i>Cancers</i> , 2022 , 14, 2532	6.6	
79	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2021 , JCO2101815	2.2	10
78	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1203-1213	2.2	15
77	The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. <i>Blood Advances</i> , 2021 , 5, 1991-2002	7.8	3
76	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. <i>Blood Advances</i> , 2021 , 5, 2438-2446	7.8	5
75	Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011). <i>Journal of Clinical Oncology</i> , 2021 , 39, 3251-3260	2.2	4
74	Deep-Learning F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 30-36	8.9	31
73	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021 , 137, 2307-2320	2.2	16
72	Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1362-1370	8.8	23
71	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021 , 137, 1765-1776	2.2	15
70	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). <i>Journal of Physical Education and Sports Management</i> , 2021 ,	2.8	1
69	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021 ,	44.5	16
68	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2605-2616	2.2	4
67	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021 , 5, 2965-2968	7.8	0
66	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021 , 13,	6.6	2

65	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.. <i>Frontiers in Immunology</i> , 2021 , 12, 755623	8.4	0
64	Shaping for PET image analysis. <i>Pattern Recognition Letters</i> , 2020 , 131, 307-313	4.7	2
63	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020 , 7, e511-e522	14.6	97
62	Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	3
61	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020 , 189, 84-96	4.5	9
60	Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. <i>Neurology</i> , 2020 , 94, e1027-e1039	6.5	44
59	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020 , 4, 3217-3223	7.8	8
58	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020 , 9, 6565-6575	4.8	11
57	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 755-757	2.2	1
56	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019 , 178, 699-713.e19	56.2	84
55	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. <i>Blood</i> , 2019 , 134, 5333-5333	2.2	1
54	Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). <i>Blood</i> , 2019 , 134, 2832-2832	2.2	3
53	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019 , 134, 1524-1524	2.2	2
52	CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria. <i>Blood</i> , 2019 , 134, 2887-2887	2.2	3
51	Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study). <i>Blood</i> , 2019 , 134, 2765-2765	2.2	
50	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , 2019 , 20, 202-215	21.7	86
49	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019 , 33, 776-780	10.7	9
48	Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from Lymphoma Study Association (LYSA) centers. <i>American Journal of Hematology</i> , 2018 , 93, 729-735	7.1	18

47	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1463-1464	8.8	12
46	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018 , 131, 1456-1463	2.2	77
45	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. <i>Blood</i> , 2018 , 132, 1629-1629	2.2	
44	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2845-2853	2.2	164
43	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 379, 934-947	59.2	168
42	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018 , 5, e403-e410	14.6	17
41	Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. <i>Blood Advances</i> , 2018 , 2, 807-816	7.8	56
40	Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?. <i>Blood</i> , 2017 , 129, 3059-3070	2.2	19
39	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1250-1260	59.2	205
38	Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1786-1794	2.2	264
37	Reply to M. Lambertini et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 805-806	2.2	1
36	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2473-2481	2.2	106
35	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3618-3626	2.2	162
34	No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2568-74	2.2	151
33	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016 , 18, 1297-303	1	80
32	Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β_2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies. <i>Blood</i> , 2016 , 128, 1101-1101	2.2	4
31	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/LYSA/FIL H10 Trial. <i>Blood</i> , 2016 , 128, 184-184	2.2	1
30	Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers. <i>Blood</i> , 2016 , 128, 3450-3450	2.2	4

29	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4202-4202	2.2	4
28	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016 , 128, 471-471	2.2	10
27	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 179-84	7.1	30
26	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015 , 2, e160-5	14.6	74
25	De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin lymphoma. <i>International Journal of Clinical Pharmacy</i> , 2015 , 37, 1033-7	2.3	
24	Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015 , 10, e0140830	3.7	65
23	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015 , 126, 335-335	2.2	5
22	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. <i>Blood</i> , 2015 , 126, 3919-3919	2.2	
21	Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 569-73	8.9	68
20	Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1735-43	8.8	105
19	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. <i>Blood</i> , 2014 , 124, 1625-1625	2.2	1
18	Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study. <i>Blood</i> , 2014 , 124, 4430-4430	2.2	
17	Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 193-9	4.4	22
16	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet</i> , 2011 , 377, 42-51	40	806
15	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet</i> , 2011 , 378, 1858-67	40	251
14	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011 , 96, 1136-43	6.6	74
13	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 118, 37-43	2.2	235
12	Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas. <i>Blood</i> , 2011 , 118, 1632-1632	2.2	1

11	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. <i>Blood</i> , 2011 , 118, 2632-2632	2.2	3
10	Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Program	2.2	
9	FCGR3A and FCGR2A Polymorphisms Do Not Affect Response and Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Study LNH2003. <i>Blood</i> , 2011 , 118, 90-90	2.2	
8	Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL). <i>Blood</i> , 2011 , 118, 2673-2673	2.2	
7	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In	2.2	21
6	Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network. Interim [18F]Fluorodeoxyglucose Positron Emission Tomography SUVmax Reduction Is Superior to Visual Analysis to Predict Early patient Outcome In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 320-320	2.2	
5	Evaluation of the Prognostic Value of CD45RO+ and FOXP3+ Cells of the Micro-Environment In Classical Hodgkin Lymphomas Using Tissue Micro Array. <i>Blood</i> , 2010 , 116, 2687-2687	2.2	
4	Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. <i>Blood</i> , 2009 , 113, 2765-3775	2.2	182
3	Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5980-7	2.2	108
2	Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci� Fran�aise de Greffe de Mo�lle Osseuse-Th�rapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2512-8	2.2	250
1	Nonclassical monocytes are prone to migrate into tumor in diffuse large B-cell lymphoma		1